ISSCA Peptide Certification: What Physicians Learn

What the ISSCA peptide certification is

The International Society for Stem Cell Application (ISSCA), based in Miami⁷, is a medical education society in regenerative medicine that offers the Advanced Peptide Therapy Certification online¹. According to the official page, the program has 9 modules and 52 sequential lessons, more than 9 hours of video, lifetime access, downloadable materials in English and Spanish, and Spanish and Portuguese subtitles. After passing an online assessment, ISSCA issues a digital certificate in the learner's name¹. It is self-paced: the page estimates that most professionals finish in 2 to 4 weeks¹.

The faculty named on the page are Dr. Greg Jones, NMD, and Dr. Jason Pencek, DC, FNP, both on the society's scientific advisory board; a new module on peptides in immunotherapy is taught by Prof. Dr. Roni Moya, PhD, an immunologist and clinical pathologist¹. ISSCA says it has certified more than 12,000 health professionals in more than 30 countries¹. For a physician deciding whether a peptide certification is worth it, the useful question is not only what the course teaches, but how much human evidence backs each topic. That is what this article reviews, area by area, with PubMed.

ISSCA's modules and the peptides they cover

The page describes the modules as: foundations; immune and inflammatory; gut; neuroendocrine and the growth hormone axis; metabolic and weight loss; sexual and reproductive; regenerative and reparative; neuromodulatory and cognitive; and a bonus module of clinical guides¹. The course says it covers more than 20 compounds, including GHRH analogs, GHRP-type secretagogues, GLP-1 and dual agonists, and repair and cognitive peptides, and it includes two of the society's own peptide books¹. The main book has chapters on BPC-157, TB-500, KPV, thymosin alpha-1, GH secretagogues, GLP-1 peptides, melanocortins, gonadotropins and LL-37.

That list mixes molecules with very different histories. Some are approved drugs tested in thousands of patients; others have one or two small trials; others rest almost entirely on rats and mice. This article does not reproduce the course material: it takes each area of the curriculum and checks it against what has been published.

Foundations and pharmacokinetics: what the literature supports

The foundations block covers what a therapeutic peptide is, how it acts on its receptors, how peptides are classified, routes of administration, basic pharmacokinetics and sourcing¹. This is solid ground: since insulin, more than 80 peptide drugs have reached the market for diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain⁸.

Pharmacokinetics is where engineered drugs and trendy peptides part ways. Semaglutide was built with two amino acid substitutions and a fatty acid chain that increases albumin binding; in mini-pigs its intravenous half-life was 46.1 hours, which made it a once-weekly candidate⁹. BPC-157, by contrast, showed an elimination half-life under 30 minutes in rats and dogs, with intramuscular bioavailability of 14–19% in rats and 45–51% in dogs, and was quickly broken down into fragments and amino acids¹⁰. A serious course should explain what that difference means before attributing any clinical effect to the molecule.

The evidence hierarchy: approved, human trials, animal-only

To evaluate the ISSCA curriculum, or any other course, it helps to sort each peptide into three tiers. The GRADE system rates the certainty of evidence and starts from the premise that randomized trials provide more certainty than observational studies¹¹. Animal studies sit one step further away: of 76 highly cited animal studies, only about a third were later replicated in human randomized trials¹².

• Approved drugs. Semaglutide and tirzepatide are FDA-approved¹³; tesamorelin was approved in November 2010 for HIV-associated lipodystrophy¹⁴; bremelanotide was approved for hypoactive sexual desire disorder in premenopausal women¹⁵; and afamelanotide is the first effective approved treatment for erythropoietic protoporphyria¹⁶.
• Controlled human trials with mixed or limited results. Thymosin alpha-1 in sepsis⁵, topical LL-37 in venous leg ulcers¹⁷¹⁸ and the oral secretagogue MK-677 in older adults¹⁹.
• Mostly preclinical data. BPC-157⁴, TB-500²⁰¹³ and KPV²¹.

Peptides in the ISSCA curriculum: what the human evidence shows

• GLP-1 and dual agonists. This is the best-supported area. In STEP 1 (1,961 adults without diabetes, 68 weeks), semaglutide reduced body weight by 14.9% vs 2.4% with placebo². In SURMOUNT-1 (2,539 adults, 72 weeks), tirzepatide achieved 15.0% to 20.9% vs 3.1% with placebo³. In both, the most common adverse events were gastrointestinal²³.
• GH secretagogues. Tesamorelin reduced visceral fat by 15.2%, vs a 5.0% increase with placebo, in 412 patients with HIV, and IGF-1 rose by 81%²². Oral MK-677 increased fat-free mass in 65 adults aged 60 to 81, but without improving strength or function, and it raised fasting glucose and lowered insulin sensitivity¹⁹.
• Melanocortins. Bremelanotide improved sexual desire and reduced related distress vs placebo in two phase 3 trials with 1,267 premenopausal women, with more nausea, flushing and headache²³. Afamelanotide lengthened pain-free sun exposure in two randomized trials in erythropoietic protoporphyria²⁴.
• Thymosin alpha-1. In the TESTS trial (1,106 adults with sepsis, 22 centers), 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (HR 0.99)⁵. More in thymosin alpha-1 after the TESTS trial.
• LL-37. In a first trial with 34 patients with venous leg ulcers, the two lowest topical concentrations sped up healing and the highest did not differ from placebo¹⁷. In the phase IIb trial with 148 patients there was no significant improvement in the full population, only a post hoc signal in large wounds¹⁸.
• BPC-157. A systematic review gathered 36 studies: 35 preclinical and 1 clinical, and found no clinical safety data⁴. That clinical study was a retrospective chart review with phone follow-up, no control group and no validated outcome tools²⁵. See the BPC-157 and TB-500 guide.
• TB-500. It is not the same as thymosin beta-4: samples of TB-500 contained the acetylated 17–23 fragment of that protein (Ac-LKKTETQ)²⁰. Published human trials use the full protein, for example thymosin beta-4 eye drops in severe dry eye with 9 patients²⁶, and TB-500 lacks an established human safety profile¹³. More in TB-500 is not thymosin beta-4.
• KPV. The tripeptide lysine-proline-valine reduced inflammation in intestinal cells and in two mouse colitis models, through the PepT1 transporter²¹. There are no controlled human trials indexed in PubMed.

Quality and the certificate of analysis: what a course should teach

The ISSCA curriculum lists sourcing and compliance among its foundations¹, and the literature shows why that module matters as much as mechanisms. In a quality-control study at Ghent University, only 44% of synthetic peptides ordered at 95% purity or higher actually met it, and one had a different structure from the one ordered; the authors warn that relying only on the supplier's certificate can have serious consequences⁶.

In semaglutide vials bought online without a prescription, measured purity was 7.7–14.4% against the 99% on the label, and every sample contained endotoxin²⁷. In falsified peptides from the Belgian market, purity of cysteine-containing peptides ranged from 5% to 75%, with arsenic and lead in several samples²⁸. A good quality module should teach how to read HPLC purity, mass spectrometry identity, net peptide content, water and endotoxin, and to ask for the lot; the practical guide is how to read a certificate of analysis.

How to evaluate the ISSCA certification or any peptide course

Before enrolling in the ISSCA certification or any other, these questions help you decide:

• Does it separate approved drugs from animal-only peptides, molecule by molecule? A 2026 review notes that many gray-market peptides show results in animals but have scarce human safety data²⁹.
• Does it cite trials with their PMIDs and also present negative results, such as TESTS or the LL-37 phase IIb trial⁵¹⁸?
• Does it publish faculty credentials? The ISSCA page lists them¹; it is also worth looking for conflict-of-interest disclosures.
• Does it teach how to read a certificate of analysis and spot falsified products⁶²⁷?
• Does it teach monitoring for known adverse effects, such as the lower insulin sensitivity reported with MK-677¹⁹?
• What do you get at the end? In this case, a digital certificate after an online assessment¹.